Osteonecrosis of the jaw and bisphosphonates: a comparison with white phosphorus, radium, and osteopetrosis (Q36939499)

17 August 2017

1 reference

title

Osteonecrosis of the jaw and bisphosphonates: a comparison with white phosphorus, radium, and osteopetrosis (English)

1 reference

17 August 2017

Michael A Vance

1

1 reference

PubMed ID

17852160

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

17 August 2017

1 reference

17 August 2017

45

1 reference

17 August 2017

7

1 reference

17 August 2017

753-762

1 reference

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

17 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteoporosis after solid organ and bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Bisphosphanates and Oral Cavity Avascular Bone Necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteonecrosis of the jaws associated with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Avascular necrosis of the jaws: risk factors in metastatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

[Bisphosphonates and osteonecrosis of the jaw]

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

The pharmacology of bisphosphonates and new insights into their mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Bisphosphonates: a review of their pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Bisphosphonates: preclinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Classical syndromes in occupational medicine: Phosphorus necrosis--a classical occupational disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Field performance measurements of half-facepiece respirators--foundry operations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Florence Kelley and the radium dial painters

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteoradionecrosis: a new concept of its pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

21 January 2018

The great radium scandal

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Review of 239Pu and 226Ra effects in beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

224Ra-induced osteopenia in male CBA mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Benign osteopetrosis: a review of 42 cases showing two different patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteomyelitis of the maxilla in a patient with osteopetrosis (Albers-Schönberg disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Neuropathic pain in maxillofacial osteonecrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteonecrosis of the jaw in patients taking bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Treatment of bone diseases with bisphosphonates, excluding osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Recommendations for zoledronic acid treatment of patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteonecrosis of the jaw and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Bisphosphonate-associated osteonecrosis of the jaw

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Thrombophilia, hypofibrinolysis, and alveolar osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

The long and the short of bone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Regarding "recommendations for zoledronic acid treatment of patients with bone metastases".

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Postmarketing surveillance--lack of vigilance, lack of trust.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteonecrosis of the jaw associated with pamidronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Bisphosphonates-related jaw osteonecrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

SOME UNRECOGNIZED DANGERS IN THE USE AND HANDLING OF RADIOACTIVE SUBSTANCES

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15563650701232505

10.1080/15563650701232505

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17852160